AstraZeneca pl, Daiichi Sankyo deal

On March 19, AstraZeneca and Daiichi partnered to co-commercialize Movantik naloxegol in the U.S. AZ will receive $200 million up front and is eligible for up to $625 million in sales milestones. AZ will book sales and make sales-related commission payments to Daiichi and is responsible for manufacturing. On March 31, AZ launched the peripheral mu opioid receptor ( OPRM1; MOR) antagonist in the U.S. to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain. The wholesale acquisition cost (WAC) is $8.32 per once-daily pill. ...